Compare Innovative Industrial Properties Inc (IIPR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Incyte Corporation — how do they compare? Innovative Industrial Properties Inc trades at $63.9 (market cap $1.87B), while Incyte Corporation trades at $115.7 (market cap $23.11B). The key difference: Incyte Corporation is far larger — about 12.4× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.81% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| IIPR | INCY | |
|---|---|---|
Market Cap | $1.87B | $23.11B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $118.52 |
52-Week Low | $44.58 | $67.38 |
Enterprise Value | $2.25B | $19.13B |
Dividend Yield | 11.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
